Involvement of HMGB1 mediated signalling pathway in diabetic retinopathy: Evidence from type 2 diabetic rats and ARPE-19 cells under diabetic condition

British Journal of Ophthalmology

Volumn 97, Issue 12, 2013, Pages 1598-1603

  Chen, Xiao Li ^a,b   Zhang, Xue Dong ^a,b   Li, Ying Yuan ^a,b   Chen, Xue Mei ^a,b   Tang, De Rong ^a,b   Ran, Rui Jin ^a,b  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b Chongqing Eye Institute   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD RETINA BARRIER; CELL NUCLEUS; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOPLASM; DIABETIC RETINOPATHY; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RAT; UPREGULATION;

IMMUNOLOGY; INFLAMMATION; PATHOLOGY; PHYSIOLOGY; RETINA;

ANIMALS; CELL SURVIVAL; CELLS, CULTURED; DIABETIC RETINOPATHY; GLUCOSE; HMGB1 PROTEIN; HUMANS; MALE; NF-KAPPA B; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, IMMUNOLOGIC; RETINA; RETINAL PIGMENT EPITHELIUM; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4;

EID: 84888644812     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2013-303736     Document Type: Article

References (20)

1. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet 2010;376:124-36.
2. Adamis AP. Is diabetic retinopathy an inflammatory disease?. Br J Ophthalmol 2002;86:363-5. (Pubitemid 34293277)
3. Adamis AP, Berman AJ. Immunological mechanisms in the pathogenesis of diabetic retinopathy. Semin Immunopathol 2008;30:65-84.
4. Chen X, Zhao Y, Zhou Z, et al. Prevalence and risk factors of diabetic retinopathy in Chongqing pre-diabetes patients. Eye (Lond) 2012;26:816-20.
5. Tang J, Kern TS. Inflammation in diabetic retinopathy. Prog Retin Eye Res 2011;30:343-58.
6. Ishida S, Usui T, Yamashiro K, et al. VEGF164 is proinflammatory in the diabetic retina. Invest Ophthalmol Vis Sci 2003;44:2155-62.
7. Yanai H, Ban T, Taniguchi T. High-mobility group box family of proteins: ligand and sensor for innate immunity. Trends Immunol 2012;33:633-40.
8. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002;418:191-5. (Pubitemid 34773774)
9. van Beijnum JR, Buurman WA, Griffioen AW. Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis 2008;11:91-9.
10. Andersson U, Tracey KJ. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol 2011;29:139-62.
11. Montemari A, Villa M, Yee K, et al. Toll-like receptor 4 expression and activity is elevated in human diabetic retinas and in retinal cells exposed to elevated glucose conditions. Invest Ophthalmol Vis Sci 2010;51:(E-Abstract)5600.
12. Pachydaki SI, Tari SR, Lee SE, et al. Upregulation of RAGE and its ligands in proliferative retinal disease. Exp Eye Res 2006;82:807-15. (Pubitemid 43170881)
13. Zong H, Ward M, Madden A, et al. Hyperglycaemia-induced pro-inflammatory responses by retinal Muller glia are regulated by the receptor for advanced glycation end-products (RAGE). Diabetologia 2010;53:2656-66.
14. Mohammad G, Siddiquei MM, Othman A, et al. High-mobility group box-1 protein activates inflammatory signaling pathway components and disrupts retinal vascular-barrier in the diabetic retina. Exp Eye Res 2013;107:101-9.
15. Xu Q, Qaum T, Adamis AP. Sensitive blood-retinal barrier breakdown quantitation using Evans blue. Invest Ophthalmol Vis Sci 2001;42:789-94. (Pubitemid 32206923)
16. Yang D, Chen Q, Yang H, et al. High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin. J Leukoc Biol 2007;81:59-66. (Pubitemid 46021253)
17. Hreggvidsdottir HS, Ostberg T, Wahamaa H, et al. The alarmin HMGB1 acts in synergy with endogenous and exogenous danger signals to promote inflammation. J Leukoc Biol 2009;86:655-62.
18. Dasu MR, Devaraj S, Park S, et al. Increased toll-like receptor (TLR) activation and TLR ligands in recently diagnosed type 2 diabetic subjects. Diabetes Care 2010;33:861-8.
19. Devaraj S, Dasu MR, Rockwood J, et al. Increased toll-like receptor (TLR) 2 and TLR4 expression in monocytes from patients with type 1 diabetes: further evidence of a proinflammatory state. J Clin Endocrinol Metab 2008;93:578-83. (Pubitemid 351240834)
20. Grigsby J, Betts B, Vidro-Kotchan E, et al. A possible role of acrolein in diabetic retinopathy: involvement of a VEGF/TGFbeta signaling pathway of the retinal pigment epithelium in hyperglycemia. Curr Eye Res 2012;37:1045-53.